前沿生物药业（南京）股份有限公司2025年度业绩预告

Core Viewpoint - Frontier Biopharmaceuticals (Nanjing) Co., Ltd. forecasts a revenue increase for 2025, while also projecting a higher net loss compared to the previous year, primarily due to the absence of investment gains from subsidiary disposals in 2024 [2][5]. Group 1: Performance Forecast - The company expects to achieve an operating revenue of approximately CNY 140 million to CNY 145 million in 2025, representing a year-on-year increase of 8.13% to 11.99% [2][5]. - The projected net loss attributable to shareholders is estimated to be between CNY 255 million and CNY 290 million, an increase in loss of approximately CNY 53.62 million to CNY 88.62 million compared to 2024 [2][5]. - The net loss excluding non-recurring gains and losses is expected to be between CNY 288 million and CNY 323 million, a reduction in loss of approximately CNY 4.31 million to CNY 39.31 million, mainly due to revenue growth and reduced expenses [2][5]. Group 2: Revenue Sources - Revenue is primarily derived from the sales of the innovative anti-HIV drug Aikening (generic name: Aibowei Tai), the agency product Viread (Tenofovir), and the newly approved far-infrared therapeutic patch (Xiaoyan Yipai) [2][5]. - The sales of Aikening are focused on the inpatient market, with continued growth in outpatient revenue, supported by its reputation as a preferred medication for hospitalized patients [5][6]. Group 3: R&D and Commercialization Progress - The company is focusing on the research and development of small nucleic acid drugs and has submitted IND applications for several candidates, including FB7013 and FB7011, which are in various stages of clinical development [7][8]. - The company has completed nationwide sales registration for the agency product Viread and has initiated commercial promotion for the far-infrared therapeutic patch [6][8]. - R&D expenses are projected to be between CNY 138 million and CNY 145 million, reflecting a year-on-year increase of 0.58% to 5.68%, as the company emphasizes early-stage development of new drugs [5][7].